This archive report was first published on 30 June 2019.
On June 30, 2019, Sanofi East Africa General Manager Peter Munyasi announced the launch of a three-month training program for over 2,000 general practitioners in Kenya.
The training, sponsored by Sanofi, aims to equip doctors with the necessary skills to manage diabetes effectively, given the shortage of endocrinologists in the country.
According to the World Health Organization, there are less than 20 endocrinologists in Kenya, a country with an estimated 460,000 people living with diabetes.
Sanofi's General Manager emphasized the importance of building capacity in diabetes management among general practitioners, stating, 'There is an intrinsic need to build capacity in diabetes management among the general practitioners in Kenya.'
Doctors who sign up for the program will access the training through the IDF School of Diabetes digital platform from a laptop or mobile phone.
The training comes at a time when Sanofi is facing challenges in the global market, including slowing sales and growing competition from generics.
Sanofi's drugs in the Kenyan market include Adlyxin, Amaryl, Apidra, Diabeta, and Lantus, which has faced criticism for its high cost in the US market.
